TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Brief Summary: The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.


Options:
A: Arm Label: Bevacizumab for ROP; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Conventional Laser for ROP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Laser for ROP | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab for ROP | Intervention Type: PROCEDURE; Name: Conventional Laser for ROP; Assigned to Arm(s): Conventional Laser for ROP
B: Arm Label: Ranibizumab alone; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab and MMC; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab and MMC | Arm Label: MMC alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: MMC | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab alone | Intervention Type: DRUG; Name: Ranibizumab and MMC; Assigned to Arm(s): Ranibizumab and MMC | Intervention Type: DRUG; Name: MMC; Assigned to Arm(s): MMC alone
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Brief Summary: The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.


Options:
A: Arm Label: ranibizumab 0.5mg; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab 0.5mg | Intervention Type: DRUG; Name: ranibizumab 0.5mg; Assigned to Arm(s): ranibizumab 0.5mg
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: Arm Label: Ranibizumab driven by disease activity; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Ranibizumab driven by stabilization criteria; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Verteporfin PDT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Verteporfin PDT, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Verteporfin PDT; Assigned to Arm(s): Verteporfin PDT | Intervention Type: DRUG; Name: Sham Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Sham verteporfin PDT; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Brief Summary: The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Brief Summary: The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.


Options:
A: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
C: Arm Label: bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): bevacizumab
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advancing INSIGHT Methods in General Practice
Brief Summary: Family Physicians, the subjects of this trial are reluctant to initiate insulin in patients with type 2 diabetes due to a lack of familiarity and comfort with this clinical strategy. This study will test the effectiveness of diabetes specialist consultation support, and community pharmacy insulin initiation support on the insulin prescribing behaviour of family physicians across Canada.


Options:
A: Arm Label: Basal Insulin Initiation Strategy; Type: EXPERIMENTAL; Interventions: Other: Basal Insulin Initiation Strategy | Arm Label: Usual Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Basal Insulin Initiation Strategy; Assigned to Arm(s): Basal Insulin Initiation Strategy
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: mobile application for diabetes | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: mobile application for diabetes; Assigned to Arm(s): Intervention
C: Arm Label: JADE; Type: EXPERIMENTAL; Interventions: Other: JADE | Arm Label: DIAMOND; Type: ACTIVE_COMPARATOR; Interventions: Other: DIAMOND | Intervention Type: OTHER; Name: JADE; Assigned to Arm(s): JADE | Intervention Type: OTHER; Name: DIAMOND; Assigned to Arm(s): DIAMOND
D: Arm Label: Control-usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention paired testing and remote monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose | Intervention Type: BEHAVIORAL; Name: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose; Assigned to Arm(s): Intervention paired testing and remote monitoring

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Safety Comparison of Intravenous Iron Dextran Versus Iron Sucrose in an Adult Non-Hemodialysis Outpatient Population: A Pilot Study
Brief Summary: The purpose of this trial is to compare the safety profile using equal doses of intravenous iron dextran versus iron sucrose. The researchers hypothesize that significantly more patients receiving intravenous iron dextran (using the current intermediate molecular weight product) will have severe adverse outcomes than patients receiving iron sucrose in the adult non-hemodialysis outpatient population. Secondly, since these severe reactions may require additional nursing time and physician interventions that may negate any cost advantage of iron dextran, the researchers hypothesize that iron sucrose will be more cost-effective than iron dextran.


Options:
A: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Anemia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid | Arm Label: Iron deficiency; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid | Arm Label: Natural comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid; Assigned to Arm(s): Anemia, Iron deficiency
C: Arm Label: Iron Dextran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron dextran | Arm Label: Iron Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron sucrose | Intervention Type: DRUG; Name: Iron dextran; Assigned to Arm(s): Iron Dextran | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): Iron Sucrose
D: Arm Label: Single oral iron supplement per day (120 mg); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Single oral iron dose of 120 mg per day for 3 consecutive days | Arm Label: B.i.d. oral iron supplement (2x 60 mg); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days | Intervention Type: DIETARY_SUPPLEMENT; Name: Single oral iron dose of 120 mg per day for 3 consecutive days; Assigned to Arm(s): Single oral iron supplement per day (120 mg) | Intervention Type: DIETARY_SUPPLEMENT; Name: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days; Assigned to Arm(s): B.i.d. oral iron supplement (2x 60 mg)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Arm Label: Varenicline + Placebo Patch; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Placebo Patch, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Arm Label: Nicotine Patch + Placebo Tablet; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: DRUG; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Placebo Tablet; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: BEHAVIORAL; Name: Counseling Sessions; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Lab Session; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Saliva Test; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline + nicotine replacement therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + nicotine replacement therapy | Intervention Type: DRUG; Name: Selegiline + nicotine replacement therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo + nicotine replacement therapy; Assigned to Arm(s): 2
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Arm Label: Smoking counseling, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking counseling, Drug: placebo | Arm Label: Smoking counseling, Varenicline; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking counseling, Drug: varenicline | Intervention Type: BEHAVIORAL; Name: Smoking counseling; Assigned to Arm(s): Smoking counseling, Placebo, Smoking counseling, Varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Smoking counseling, Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Smoking counseling, Placebo
B: Arm Label: Combination zonisamide and bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Zonisamide, Other: E-cigarette | Arm Label: Bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Arm Label: Placebo with e-cigarette; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Placebo bupropion; Assigned to Arm(s): Placebo with e-cigarette | Intervention Type: DRUG; Name: Placebo zonisamide; Assigned to Arm(s): Bupropion with e-cigarette, Placebo with e-cigarette | Intervention Type: OTHER; Name: E-cigarette; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette, Placebo with e-cigarette
C: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Smoking counseling, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking counseling, Drug: placebo | Arm Label: Smoking counseling, Varenicline; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking counseling, Drug: varenicline | Intervention Type: BEHAVIORAL; Name: Smoking counseling; Assigned to Arm(s): Smoking counseling, Placebo, Smoking counseling, Varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Smoking counseling, Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Smoking counseling, Placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)
Brief Summary: The primary objective of this protocol is to evaluate 12 weeks of treatment of varenicline compared to placebo for smoking cessation. Abstinence from cigarette smoking and other tobacco products (e.g., pipe, cigars, chew, snuff.) use during non-treatment follow-up period will also be evaluated.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D